OncoImmune
Latest round
- Series B
Last raised
- Sep 2020
Total raised
- $71M
Investors
- 5
About OncoImmune
, the developer of CD24Fc, a prophylactic treatment for Graft versus Host Disease (GvHD) of leukemia patients that undergoes hematopoietic stem cell transplantation. The company's pharmaceutical also provides treatment for cancer and autoimmune diseases.
Who invested in OncoImmune
5 investors across 2 rounds
See all investors in OncoImmune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about OncoImmune
Who invested in OncoImmune?
OncoImmune has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has OncoImmune raised?
OncoImmune has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did OncoImmune last raise money?
OncoImmune's most recent round on record is a Series B, in Sep 2020.
What does OncoImmune do?
, the developer of CD24Fc, a prophylactic treatment for Graft versus Host Disease (GvHD) of leukemia patients that undergoes hematopoietic stem cell transplantation.
Where is OncoImmune headquartered?
OncoImmune is headquartered in Rockville, US.
Which VCs invest in companies like OncoImmune?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at OncoImmune's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like OncoImmune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.